Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-1.04 · Revenue $12.39M · 14 analysts
Est. EPS $-0.17 · Revenue $1.68M · 7 analysts
Est. EPS $-0.15 · Revenue $5.68M · 4 analysts
Est. EPS $-0.71 · Revenue $12.70M · 12 analysts
EPS $-0.24 · Revenue $4.37M
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $14.2M | +29.1% | -65.0% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-49.6M | +13.8% | +87.6% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +100.0% | 0.0% | +0.6% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -271.9% | +51.9% | -227.8% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -349.3% | +33.3% | +64.7% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-35.3M | -37.8% | +6.1% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -248.3% | -6.7% | -168.3% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 0.0% | — | -375.4% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 6.43x | +98.4% | +70.9% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $50.2M | +36.3% | +39.2% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -0.80 vs -0.67 | -19.9% | -0.08 vs -0.17 | +52.0% |
| Revenue Surprise | $14.2M vs $13.5M | +5.3% | $755000 vs $1.7M | -55.1% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Jul 23, 2026 | YERXA BENJAMIN R | director, officer: President | Common Stock | D | 7,429 | $2.97 |
| Jul 23, 2026 | SCHACHLE JOSEPH K | officer: Chief Operating Officer | Common Stock | D | 4,644 | $2.94 |
| Jul 23, 2026 | Magrath George | director, officer: Chief Executive Officer | Common Stock | D | 9,475 | $2.95 |
| Jul 23, 2026 | Gagnon Robert E. | officer: Chief Financial Officer | Common Stock | D | 7,783 | $2.95 |
| May 18, 2026 | Foundation Fighting Blindness Retinal Degeneration Fund | director, other: See Remarks | Common Stock | D | 1,700,000 | $4.35 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
George Magrath | Chief Executive Officer & Director | USD 973,790 | Male | 1985 | Active |
Ashwath Jayagopal | Chief Scientific & Development Officer | USD 682,360 | — | 1983 | Active |
Joseph K. Schachle | Chief Operating Officer | USD 635,920 | Male | 1965 | Active |
Amy Zaremba Rabourn | Head of Financial Quality Assurance | USD 434,100 | Female | 1981 | Active |
Bernhard Hoffmann | Senior Vice President of Corporate Development & Secretary | USD 434,100 | Male | 1956 | Active |
Chris Ernst | Chief Technology Officer | — | Male | — | Active |
Robert E. Gagnon | Chief Financial Officer & Principal Accounting Officer | — | Male | 1974 | Active |
Jenny Kobin | Investor Relations Officer | — | Female | — | Active |
Benjamin R. Yerxa | President & Director | — | — | 1966 | Active |
Sally Tucker | Chief Medical Officer & Senior Vice President of Clinical Development | — | Female | — | Active |
Bindu Manne | Head of Market Development & Commercialization | — | Female | — | Active |
ADAR1 Capital Management LLC acquired a new position in Opus Genetics, Inc. (NASDAQ: IRD) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 1,783,781 shares of the company's stock, valued at approximately $7,331,000. ADAR1 Capital Management LLC owned 2.16% of Opus Genetics
RESEARCH TRIANGLE PARK, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) (the “Company”), today announced that the Compensation Committee of its Board of Directors approved equity awards under the Company's 2021 Inducement Plan, as amended, as a material inducement to employment to three non-executive employees who were not previously employees or directors of the Company.
Opus Genetics, Inc. (IRD) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.12 per share a year ago.
Topline six-month efficacy data expected by end of 2027 Phase 3 study follows FDA alignment on registrational trial design through Rare Disease Evidence Principles (RDEP) program Opus Genetics may submit a BLA based on 6-month efficacy data, with 12-month durability data provided during review RESEARCH TRIANGLE PARK, N.C., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that the last patient has been enrolled in its registrational Phase 3 clinical trial evaluating OPGx-LCA5, the Company's investigational gene therapy for LCA5-associated inherited retinal disease.
RESEARCH TRIANGLE PARK, N.C., July 09, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company”, “Opus Genetics” or “Opus”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today provided updates on its ongoing OPGx-BEST1 Phase 1/2 clinical trial (BIRD-1) targeting BEST-1 associated IRDs.
